Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naive & experienced metastatic melanoma patients

被引：7
|
作者：
Leung, Abraham C. F.
Kummar, Shivaani
Agarwala, Sanjiv S.
Nemunaitis, John J.
Gonzalez, Rene
Drabick, Joseph J.
Schmidt, Emmett V.
Chartash, Elliot
Xing, Biao
Currie, Graeme
Janssen, Robert
Ribas, Antoni
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9550
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
    Nakamura, Y.
    Namikawa, K.
    Yoshino, K.
    Yoshikawa, S.
    Uchi, H.
    Goto, K.
    Fukushima, S.
    Kiniwa, Y.
    Takenouchi, T.
    Uhara, H.
    Kawai, T.
    Hatta, N.
    Funakoshi, T.
    Teramoto, Y.
    Otsuka, A.
    Doi, H.
    Ogata, D.
    Matsushita, S.
    Isei, T.
    Hayashi, T.
    Shibayama, Y.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1198 - 1206
  • [32] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    CANCER RESEARCH, 2017, 77
  • [33] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Diab, Sami
    CANCER RESEARCH, 2018, 78 (04)
  • [34] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia
    Savulsky, Claudio
    Olivo, Martin
    Aktan, Gursel
    Kaufman, Peter A.
    Xing, Dongyuan
    Almonte, Ana
    Misir, Soamnauth
    Karantza, Vassiliki
    Young, Louise
    Diab, Sami
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 176 - 176
  • [35] Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Tolaney, S.
    Savulsky, C.
    Aktan, G.
    Xing, D.
    Almonte, A.
    Karantza, V.
    Diab, S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S16 - S16
  • [36] Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
    Naoya Yamazaki
    Tatsuya Takenouchi
    Manabu Fujimoto
    Hironobu Ihn
    Hiroshi Uchi
    Takashi Inozume
    Yoshio Kiyohara
    Hisashi Uhara
    Kazuhiko Nakagawa
    Hiroshi Furukawa
    Hidefumi Wada
    Kazuo Noguchi
    Takashi Shimamoto
    Kenji Yokota
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 651 - 660
  • [37] Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study
    Ridolfi, Laura
    De Rosa, Francesco
    Petracci, Elisabetta
    Tanda, Enrica Teresa
    Marra, Elena
    Pigozzo, Jacopo
    Marconcini, Riccardo
    Guida, Michele
    Cappellini, Gian Carlo Antonini
    Gallizzi, Giulia
    Occelli, Marcella
    Pala, Laura
    Gambale, Elisabetta
    Bersanelli, Melissa
    Galdo, Giovanna
    Cortellini, Alessio
    Morgese, Francesca
    Zoratto, Federica
    Stucci, Luigia Stefania
    Strippoli, Sabino
    Guidoboni, Massimo
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (03) : 515 - 522
  • [38] Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study
    Rugo, Hope S.
    Kabos, Peter
    Beck, J. Thad
    Jerusalem, Guy
    Wildiers, Hans
    Sevillano, Elena
    Paz-Ares, Luis
    Chisamore, Michael J.
    Chapman, Sonya C.
    Hossain, Anwar M.
    Chen, Yanyun
    Tolaney, Sara M.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [39] Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
    Hope S. Rugo
    Peter Kabos
    J. Thad Beck
    Guy Jerusalem
    Hans Wildiers
    Elena Sevillano
    Luis Paz-Ares
    Michael J. Chisamore
    Sonya C. Chapman
    Anwar M. Hossain
    Yanyun Chen
    Sara M. Tolaney
    npj Breast Cancer, 8
  • [40] Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
    Yamazaki, Naoya
    Takenouchi, Tatsuya
    Fujimoto, Manabu
    Ihn, Hironobu
    Uchi, Hiroshi
    Inozume, Takashi
    Kiyohara, Yoshio
    Uhara, Hisashi
    Nakagawa, Kazuhiko
    Furukawa, Hiroshi
    Wada, Hidefumi
    Noguchi, Kazuo
    Shimamoto, Takashi
    Yokota, Kenji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 651 - 660
12345